The abstract is read at the publisher; the summary is JClub's.
In cholangiocarcinoma, intrahepatic, perihilar, and distal anatomic subtypes are distinct tumor entities, not one disease, with differences spanning biology and clinical behavior.
- Why it matters: The field needs precision medicine because diagnosis, treatment responsiveness, and prognosis vary across subtypes, while global incidence is rising.
- What they did: The review synthesizes evidence that each subtype differs in embryologic origin, carcinogenesis, molecular landscape, and immunogenic profile, and links these to risk factors, AI diagnostics, surgical tailoring, and molecular/immune-guided therapy.
- The result: Recognizing subtype-specific biology supports improved clinical management and helps guide future research, including early diagnosis and chemoprevention in high-risk populations.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.